Skip to main content
OpenTrials
Completed

NCT Number: NCT04968405

Catalyst CSR Shoulder System for Semi or Total Shoulder Arthroplasty

Evaluation of the performance and safety of the Catalyst CSR Shoulder System with clinical and radiographic results at multiple time points through 24 months postoperatively This study will be a prospective multi-center study conducted in the United States.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Beaumont Hospital Royal Oak, Royal Oak, Michigan, United States

Loading trial locations.

About this study

The purpose of this study is to assess the performance and safety of the Catalyst CSR Shoulder System in skeletally mature patients with degenerative disease of the glenohumeral joint where hemi or total shoulder arthroplasty is determined by the surgeon to be the preferred method of treatment. Patients who sign informed consent and meet the inclusion/exclusion criteria will have the Catalyst CSR Shoulder system implanted at participating sites. Data will be collected at baseline (pre-operative), perioperatively, and postoperatively at 3 months, 6 months, 12 months and 24 months. This study is expected to take 36 months to complete.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 years of age or older
  • Patient must be skeletally mature with degenerative disease of the glenohumeral joint where hemi or total shoulder arthroplasty
  • Meets the Catalyst CSR Shoulder System Indications for Use according to approved labeling

Exclusion criteria

  • Has a history of open surgery to index shoulder prior to treatment with the Catalyst CSR system? (history of previous arthroscopic surgery allowed)
  • Has a full thickness rotator cuff tear diagnosed by MFI or marked posterior glenoid wear
  • Patient is unwilling or unable to comply with the post-operative care instructions, attend follow visits per the study schedule and complete the study assessments (i.e., Pros)
  • The patient is a non-English speaker
  • In the opinion of the investigator, is it not in the patient's best interest to participate in this study
  • Local or systemic infection, or osteomyelitis of the proximal humerus or scapula; if a systemic infection or a secondary remote infection is suspected or confirmed, joint replacement surgery should be delayed until infection is resolved
  • Inadequate or malformed bone that precludes adequate support of fixation of the prosthesis
  • Osteoporosis
  • Neuromuscular disorders that do not allow control of the joint
  • Chronic instability, chronic dislocation or deficient soft tissues and other support structures (e.g., brachial plexus or deltoid muscles)
  • Vascular insufficiency
  • Subject's age, weight or activity level cause the surgeon to expect early failure of the system
  • The patient is unwilling to comply or unable to comply with the post-operative care instructions
  • Alcohol, drug, substance abuse or other conditions that would affect or impair the patient from complying with post-operative instructions
  • Patients with known sensitivity to Co-Cr-Mo alloys typically used prosthetic devices
  • Any disease that could adversely affect the function or expected longevity of the implants (e.g., metabolic disorders)

Treatment and study plan

Catalyst CSR Total Shoulder System

Device

The Catalyst CSR Shoulder System is a bone preserving total shoulder prosthesis designed for use in patients where the humeral head, neck and glenoid vault are of sufficient bone stock and there is an intact or reconstructable rotator cuff. The design requires minimal bone resection, thus giving the patient an alternative to other total shoulder designs where more bone is removed.

Primary outcomes

  1. American Shoulder and Elbow Surgeons (ASES) Assessment Questionnaire

    Time frame: 12 Months

    Change from baseline in patient reported outcome scores using the ASES

Secondary outcomes

  1. Radiographic Assessment

    Time frame: 3 months, 6 months, 12 months, 24 months

    Lack of radiographic evidence of osteolysis, stress shielding or lucent line formation through a minimum of 12-months post operation.

  2. Range of Motion Assessment

    Time frame: Baseline, 3 months, 6 months, 12 months, 24 months

    Change active range of motion (ROM) from baseline (preoperative)

  3. American Shoulder and Elbow Surgeons (ASES) Assessment Questionnaire

    Time frame: Baseline 3 months, 6 months, 12 months, 24 months

    Change from baseline in patient reported outcome scores using the ASES

  4. PROMIS Physical and Mental Function (PROMIS GLOBAL-10) Questionnaire

    Time frame: Baseline 3 months, 6 months, 12 months, 24 months

    Change from baseline in patient reported outcome scores using the PROMIS

  5. Single Assessment Numeric Evaluation (SANE)

    Time frame: Baseline 3 months, 6 months, 12 months, 24 months

    Change from baseline in patient reported outcome scores using the SANE

  6. Visual Analog Score (VAS) Scale

    Time frame: Baseline 3 months, 6 months, 12 months, 24 months

    Change from baseline in patient reported outcome scores using the VAS

  7. Patient Satisfaction Assessment

    Time frame: 6, 12 and 24 months

    Patient Satisfaction

Other outcomes

  1. Patient Safety

    Time frame: perioperatively, 3, 6, 12 and 24 months

    Report of adverse events/serious adverse event rates related to the procedure or device

    • Implant removal rate
    • Revision rate

Sponsors and collaborators

Lead sponsor

Catalyst OrthoScience

Industry

Registry information

Official study title

Analysis of the Performance and Safety of the Catalyst CSR Shoulder System - A Prospective Study

Important dates

Study start
2022
Primary completion
2026
Study completion
2026
First posted
Jul 20, 2021
Registry last updated
Mar 31, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.